MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

NGS lab-developed tests and FDA-approved/cleared NGS clinical laboratory tests are covered for diagnosis and management of myeloid malignancies and suspected myeloid neoplasms under NCD 90.2 and applicable MAC discretion. The policy is limited to myeloid indications and explicitly excludes solid tumor testing, circulating tumor DNA (ctDNA) testing, germline testing, and other non-myeloid cancer-related uses of NGS.

"Next-Generation Sequencing (NGS) lab-developed tests (LDTs) and FDA-approved or -cleared clinical laboratory NGS tests are covered for diagnosis and management of myeloid malignancies and suspected..."

Sign up to see full coverage criteria, indications, and limitations.